| P2093 | author name string | Nicholas Moore | |
| | Alexandre Boyer | |
| | Benjamin Clouzeau | |
| | Didier Gruson | |
| | Frédéric Vargas | |
| | Mathieu Molimard | |
| | Stéphane Bouchet | |
| | Anne-Marie Rogues | |
| | Bui Hoang-Nam | |
| | Hilbert Gilles | |
| P2860 | cites work | Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group | Q21195082 |
| | A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients | Q28325426 |
| | Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin | Q28327231 |
| | Amikacin nephrotoxicity in patients with chronic liver disease | Q28332489 |
| | Validation and nephrotoxicity of a simplified once-daily aminoglycoside dosing schedule and guidelines for monitoring therapy | Q28379292 |
| | Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials | Q30756968 |
| | Using local microbiologic data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia | Q31060242 |
| | Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis | Q31143077 |
| | Critical care of the bariatric patient | Q33239556 |
| | Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials | Q33287379 |
| | The economic impact of once-daily versus conventional administration of gentamicin and tobramycin | Q33573691 |
| | Aminoglycosides: nephrotoxicity | Q33605648 |
| | Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring | Q33645586 |
| | Population pharmacokinetic study of amikacin administered once or twice daily to febrile, severely neutropenic adults | Q33692660 |
| | Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria | Q33976467 |
| | Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man | Q43467285 |
| | Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs | Q43580192 |
| | Experience with a once-daily dosing program of aminoglycosides in critically ill patients | Q44067363 |
| | Gender differences in aminoglycoside induced nephrotoxicity: a prospective, hospital-based study | Q44127798 |
| | More data on epidemiology and outcome of acute kidney injury with AKIN criteria: benefits of standardized definitions, AKIN and RIFLE classifications | Q44137656 |
| | Diuretics, mortality, and nonrecovery of renal function in acute renal failure | Q44224613 |
| | Effect of once-daily dosing vs. multiple daily dosing of tobramycin on enzyme markers of nephrotoxicity | Q44245415 |
| | Algorithm for assessing renal dysfunction risk in critically ill trauma patients receiving aminoglycosides | Q44273352 |
| | Aminoglycoside-associated nephrotoxicity in the elderly | Q44292352 |
| | Pharmacokinetic dosing of aminoglycosides: a controlled trial | Q44361848 |
| | Recommended dose of arbekacin, an aminoglycoside against methicillin-resistant Staphylococcus aureus, does not achieve desired serum concentration in critically ill patients with lowered creatinine clearance | Q44394213 |
| | Aminoglycoside dosages and nephrotoxicity: quantitative relationships | Q44436107 |
| | A study of once-daily amikacin with low peak target concentrations in intensive care unit patients: pharmacokinetics and associated outcomes | Q44473953 |
| | Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 |
| | Clinical predictors of subtherapeutic aminoglycoside levels in trauma patients undergoing once-daily dosing | Q44546045 |
| | An information campaign on aminoglycosides use during septic shock failed to improve the quality of care | Q44639383 |
| | Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database. | Q45957694 |
| | Severity of gentamicin's nephrotoxic effect on patients with infective endocarditis: a prospective observational cohort study of 373 patients. | Q46221326 |
| | Case-control study of acute renal failure in patients with cystic fibrosis in the UK. | Q46775504 |
| | Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients: a quasi experimental study | Q46943794 |
| | Serum level monitoring of aminoglycoside antibiotics. Limitations in intensive care unit-related bacterial pneumonia | Q47648271 |
| | Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine | Q50457858 |
| | A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. | Q50509585 |
| | A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. | Q50509590 |
| | Impact of a clinical pharmacokinetic service on patients treated with aminoglycosides: a cost-benefit analysis. | Q50550856 |
| | Acute renal failure in intensive care units--causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. | Q51036322 |
| | Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved? | Q51907741 |
| | Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. | Q51930719 |
| | Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. | Q52071390 |
| | A concept for pharmacokinetic-pharmacodynamic dosage adjustment in renal impairment: the case of aminoglycosides. | Q52078881 |
| | Isepamicin in intensive care unit patients with nosocomial pneumonia: population pharmacokinetic-pharmacodynamic study. | Q52206525 |
| | Can pharmacokinetic dosing decrease nephrotoxicity associated with aminoglycoside therapy. | Q52393812 |
| | A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration. | Q52447951 |
| | Evaluation of a Bayesian method of amikacin dosing in intensive care unit patients with normal or impaired renal function. | Q52594977 |
| | Comparison of four methods of predicting serum gentamicin concentrations in adult patients with impaired renal function. | Q52718346 |
| | Rotation and restricted use of antibiotics in a medical intensive care unit. Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria. | Q54036846 |
| | Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity | Q33977062 |
| | Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring | Q34061646 |
| | Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury | Q34108507 |
| | Influence of empiric therapy with a beta-lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to gram-negative microorganisms. | Q34108527 |
| | Does once-daily dosing prevent nephrotoxicity in all aminoglycosides equally? | Q34135494 |
| | New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. | Q34139570 |
| | Update on drug sieving coefficients and dosing adjustments during continuous renal replacement therapies. | Q34275784 |
| | Risk factors for the development of renal dysfunction in hospitalized patients with cirrhosis | Q34316216 |
| | A suggested approach to once‐daily aminoglycoside dosing | Q34347273 |
| | A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses | Q34389944 |
| | Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? | Q34458340 |
| | Aminoglycoside nephrotoxicity: modeling, simulation, and control | Q34735262 |
| | Risk factors for toxicity in elderly patients given aminoglycosides once daily. | Q34752229 |
| | Do we still need the aminoglycosides? | Q34870194 |
| | Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic | Q34941521 |
| | Optimization of aminoglycoside therapy | Q35005127 |
| | Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone | Q35025773 |
| | Population pharmacokinetics of amikacin in critically ill patients | Q35125654 |
| | Administration of aminoglycosides to hemodialysis patients immediately before dialysis: a new dosing modality | Q35139187 |
| | Simplified estimation of aminoglycoside pharmacokinetics in underweight and obese adult patients | Q35191383 |
| | Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration | Q35270646 |
| | The use of a change in gentamicin clearance as an early predictor of gentamicin-induced nephrotoxicity | Q35543018 |
| | Proposal of a pharmacokinetically optimized dosage regimen of antibiotics in patients receiving continuous hemodiafiltration | Q35598435 |
| | Bactericidal antibiotics temporarily increase inflammation and worsen acute kidney injury in experimental sepsis | Q35663183 |
| | Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients | Q35668521 |
| | Comparative nephrotoxicity of gentamicin and tobramycin: pharmacokinetic and clinical studies in 201 patients | Q35669927 |
| | Comparison of standard versus pharmacokinetically adjusted amikacin dosing in granulocytopenic cancer patients | Q35714140 |
| | Endotoxemia, renal hypoperfusion, and fever: interactive risk factors for aminoglycoside and sepsis-associated acute renal failure | Q35804349 |
| | Gentamicin and gram-negative bacteremia. A synergism for the development of experimental nephrotoxic acute renal failure | Q35808241 |
| | Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients | Q35867436 |
| | Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. | Q36053463 |
| | Clinical and economic outcomes of pharmacist-managed aminoglycoside or vancomycin therapy | Q36200765 |
| | Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy | Q36257693 |
| | An approach to forecast aminoglycoside-related nephrotoxicity from routinely collected clinical data | Q36438906 |
| | Usefulness of estimating individual pharmacokinetic data for aminoglycoside therapy in seriously ill patients | Q36457502 |
| | Drug-associated renal dysfunction. | Q36469777 |
| | Contrast-induced nephropathy--prevention and risk reduction | Q36488531 |
| | Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team | Q36546930 |
| | Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing | Q36666776 |
| | Back to the future: using aminoglycosides again and how to dose them optimally | Q36916092 |
| | Optimizing use of aminoglycosides in the critically ill. | Q37038577 |
| | An overview of drug-induced acute kidney injury | Q37125735 |
| | Prevalence and risk factors for aminoglycoside nephrotoxicity in intensive care units | Q37247721 |
| | Clinical and economic outcomes of involving pharmacists in the direct care of critically ill patients with infections | Q37303821 |
| | Aminoglycoside drugs in clinical practice: an evidence-based approach | Q37331044 |
| | Suboptimal aminoglycoside dosing in critically ill patients | Q37341556 |
| | Pharmacist-driven aminoglycoside quality improvement program | Q37417871 |
| | Gentamicin-induced nephrotoxicity: Do we have a promising therapeutic approach to blunt it? | Q37740458 |
| | Molecular-targeted approaches to reduce renal accumulation of nephrotoxic drugs | Q37763924 |
| | A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study | Q37766420 |
| | Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis | Q37816006 |
| | Antibiotic dosing during sustained low-efficiency dialysis: special considerations in adult critically ill patients | Q37827317 |
| | Clinical implications of β-lactam-aminoglycoside synergism: systematic review of randomised trials | Q37835513 |
| | Antibiotic dosing in critical illness | Q37852466 |
| | Prospective audit of aminoglycoside usage in a general hospital with assessments of clinical processes and adverse clinical outcomes. | Q38950978 |
| | Evaluation of four once-daily aminoglycoside dosing nomograms | Q39221496 |
| | Once versus thrice daily gentamicin in patients with serious infections | Q39369365 |
| | Improved efficacy with nonsimultaneous administration of first doses of gentamicin and ceftazidime in vitro | Q39778914 |
| | Experience with a once-daily aminoglycoside program administered to 2,184 adult patients | Q39779327 |
| | Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center | Q39980070 |
| | Does aminoglycoside therapy cause significant acute kidney injury in febrile neutropenia? | Q40340461 |
| | Amikacin Bayesian forecasting in critically ill patients with sepsis and cirrhosis | Q40893128 |
| | Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity | Q40902529 |
| | Gentamicin clearance during continuous arteriovenous hemodiafiltration. | Q41118702 |
| | Single or multiple daily doses of aminoglycosides: a meta-analysis | Q42145555 |
| | Risk Factors for Nephrotoxicity in Patients Treated with Aminoglycosides | Q42247725 |
| | Low serum albumin and the increased risk of amikacin nephrotoxicity | Q42284182 |
| | Nephrotoxicity of vancomycin and aminoglycoside therapy separately and in combination | Q42286407 |
| | Management of Aminoglycosides in the Intensive Care Unit | Q42908869 |
| | Effect of furosemide on aminoglycoside-induced nephrotoxicity and auditory toxicity in humans | Q42928339 |
| | Gentamicin-associated acute kidney injury | Q43263735 |
| | Evaluation of "Loss" and "End stage renal disease" after acute kidney injury defined by the Risk, Injury, Failure, Loss and ESRD classification in critically ill patients | Q43276182 |
| | Effect of a single dose of tobramycin on systemic inflammatory response-induced acute kidney injury in a 6-hour porcine model | Q43286162 |
| | A prospective randomised trial comparing individualised pharmacokinetic dosage prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients | Q43446209 |
| | Efficacy and safety of once-daily amikacin in combination with ceftazidime in critically ill adults with severe gram-negative infections. | Q54576022 |
| | Monitoring aminoglycoside use in patients with severely impaired renal function | Q55496350 |
| | Gentamicin volume of distribution in critically ill septic patients | Q57238214 |
| | Development of a Semimechanistic Model to Describe the Pharmacokinetics of Gentamicin in Patients Receiving Hemodialysis | Q59621175 |
| | Renal tolerability of four different once-daily dose regimen of netilmicin in critical care patients | Q62516255 |
| | Gentamicin disposition and tissue accumulation on multiple dosing | Q67053863 |
| | Comparative studies on the action of aminoglycosides and cephalosporins on the proximal tubule of the human kidney | Q67342109 |
| | Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients | Q67779622 |
| | Variability in aminoglycoside pharmacokinetics in critically ill surgical patients | Q68287019 |
| | Gentamicin nephrotoxicity in the setting of acute renal hypoperfusion | Q68304811 |
| | Does accepting pharmacokinetic recommendations impact hospitalization? A cost-benefit analysis | Q68378554 |
| | Prospective comparison of traditional and pharmacokinetic aminoglycoside dosing methods | Q68465414 |
| | Pharmacokinetics of amikacin during continuous veno-venous hemofiltration | Q68796364 |
| | Impact of aminoglycoside serum assays on clinical decisions and renal toxicity | Q68862933 |
| | Pharmacokinetic monitoring of nephrotoxic antibiotics in surgical intensive care patients | Q69387065 |
| | What is the cost of nephrotoxicity associated with aminoglycosides? | Q69462800 |
| | A model for predicting nephrotoxicity in patients treated with aminoglycosides | Q69493303 |
| | Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients | Q69694486 |
| | Aminoglycoside dosage in hemodialysis patients | Q69694488 |
| | The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function | Q69796060 |
| | Once-daily dosing decreases renal accumulation of gentamicin and netilmicin | Q69936275 |
| | The clinical utility of a published nomogram to predict aminoglycoside nephrotoxicity | Q69997366 |
| | Aminoglycoside dosing in renal transplant patients. Comparison of nomogram and individualized pharmacokinetic methods in patients with shifting renal function | Q70217612 |
| | Increased burn patient survival with individualized dosages of gentamicin | Q70277778 |
| | Cost-benefit analysis of an aminoglycoside monitoring service | Q70291520 |
| | Effect of furosemide on the pharmacokinetics of gentamicin in patients | Q70430086 |
| | Gentamicin dosing errors with four commonly used nomograms | Q70432512 |
| | Optimizing tobramycin therapy in a hemodialysis patient | Q70452695 |
| | Physiologic response of stress and aminoglycoside clearance in critically ill patients | Q70549295 |
| | Audit of prescription and assay of aminoglycosides in a UK teaching hospital | Q70769444 |
| | Aminoglycoside volume of distribution and illness severity in critically ill septic patients | Q70776962 |
| | Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia | Q71059881 |
| | Prediction of serum gentamicin concentrations in patients undergoing hemodialysis | Q71286931 |
| | Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient | Q71510537 |
| | A Randomized Clinical Trial of Moxalactam Alone versus Tobramycin plus Clindamycin in Abdominal Sepsis | Q72787093 |
| | Assessment of the enzymuria resulting from gentamicin alone and combinations of gentamicin with various beta-lactam antibiotics | Q73418857 |
| | Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis | Q73425751 |
| | National survey of extended-interval aminoglycoside dosing | Q73560643 |
| | Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients | Q73562544 |
| | Pharmacoeconomic impact of once-daily aminoglycoside administration | Q73571439 |
| | Appropriateness of a 4 mg/kg gentamicin or tobramycin loading dose in post-operative septic shock patients | Q77611661 |
| | Factors affecting gentamicin pharmacokinetics in septic patients | Q78156677 |
| | Gentamicin and acute kidney injury requiring renal replacement therapy in the context of a restrictive antibiotic policy | Q84189297 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sepsis | Q183134 |
| | septic shock | Q1765564 |
| P304 | page(s) | 217-230 | |
| P577 | publication date | 2013-04-01 | |
| P1433 | published in | Drug Safety | Q15724462 |
| P1476 | title | Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk | |
| P478 | volume | 36 | |